PAVmed (PAVM) Stock Price, News & Analysis

Company Overview

PAVmed Inc. is a diversified medical technology company that develops and commercializes diagnostic and therapeutic products intended to address significant unmet needs in healthcare. Its portfolio has included medical devices, diagnostic technologies and digital health solutions, with a focus on products designed to improve disease detection, treatment and patient care.

One of PAVmed’s principal areas of activity has been its relationship with Lucid Diagnostics, a subsidiary focused on early detection of esophageal disease. Lucid’s EsoGuard molecular diagnostic test is designed to identify abnormal cells associated with Barrett’s esophagus, while the EsoCheck device is intended to collect esophageal cells in a noninvasive office-based procedure. PAVmed has also developed medical devices such as CarpX, a system designed to support minimally invasive carpal tunnel release procedures.

PAVmed was founded in 2014 by physician and entrepreneur Lishan Aklog, who has served as chairman and chief executive officer. The company is headquartered in New York and has focused primarily on developing healthcare technologies for the U.S. market, while seeking broader commercial opportunities as its products advance through regulatory and commercialization processes.

Key Stats

• Today's Range: $2.15 to $2.26
• 50-Day Range: $2.05 to $5.35
• 52-Week Range: $1.84 to $28.44
• Volume: 4,406 shs
• Average Volume: 21,348 shs
• Market Capitalization: $18.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $56.00
• Consensus Rating: Hold

PAVmed Stock Analysis - MarketRank™

PAVmed scored higher than 47% of companies evaluated by MarketBeat, and ranked 562nd out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

PAVmed has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

PAVmed has a consensus price target of $56.00, representing about 2,377.9% upside from its current price of $2.26.

Amount of Analyst Coverage

PAVmed has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for PAVmed are expected to grow in the coming year, from ($2.74) to ($2.55) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of PAVmed is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of PAVmed is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.18% of the float of PAVmed has been sold short.

Short Interest Ratio / Days to Cover

PAVmed has a short interest ratio ("days to cover") of 0.46, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in PAVmed has recently increased by 0.76%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PAVmed does not currently pay a dividend.

Dividend Growth

PAVmed does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.25

News Sentiment

PAVmed has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for PAVmed this week, compared to 2 articles on an average week.

MarketBeat Follows

3 people have added PAVmed to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, PAVmed insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.40% of the stock of PAVmed is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

19.93% of the stock of PAVmed is held by institutions.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 10/26/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:PAVM
• CIK: 1624326
• Web: www.pavmed.com
• Phone: (212) 949-4319
• Fax: N/A
• Employees: 41
• Year Founded: 2014

Price Target and Rating

• Average Price Target for PAVmed: $56.00
• High Price Target: $56.00
• Low Price Target: $56.00
• Potential Upside/Downside: +2,377.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($16.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $400 thousand
• Net Margins: -10,794.64%
• Pretax Margin: -14,669.64%
• Return on Equity: -126.43%
• Return on Assets: -25.49%

Debt

• Debt-to-Equity Ratio: 0.98
• Current Ratio: 1.19
• Quick Ratio: 1.19

Sales & Book Value

• Annual Sales: $70 thousand
• Price / Sales: 258.29
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.42) per share
• Price / Book: -0.93

Miscellaneous

• Outstanding Shares: 8,000,000
• Free Float: 6,925,000
• Market Cap: $18.08 million
• Optionable: No Data
• Beta: 0.69